TBIQYR1705-Global Irritable Bowel Syndrome (IBS) Market Research Report 2019

                                          
Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS is among the most common gastrointestinal disorders, with an estimated pooled international IBS prevalence rate of about 11.2%.
Currently, the IBS treatment market is naïve and underpenetrated, with 4 products indicated for IBS in the market. These include the IBS-C therapies, Amitiza (lubiprostone, Sucampo/Takeda) and Linzess (linaclotide, Ironwood/Allergan/Astellas); and the IBS-D therapies, Lotronex (Sebela Pharmaceuticals) and Irribow (ramosetron, Astellas). Antidepressants and antibiotics (mainly Xifaxan [rifaximin], Valeant) are also used off-label to treat IBS.
The IBS treatment market is characterized by significant unmet needs, which include the need for products with improved efficacy, products for the treatment of the IBS-D and IBS-M subtypes, and products that effectively address IBS symptoms, such as abdominal pain and bloating, as well as the requirement for the improved diagnosis of IBS. As a result, there are significant opportunities in the uncrowded IBS therapeutics market.

The global Irritable Bowel Syndrome (IBS) market is valued at 2640 million US$ in 2018 is expected to reach 8650 million US$ by the end of 2025, growing at a CAGR of 16.0% during 2019-2025.
This report focuses on Irritable Bowel Syndrome (IBS) volume and value at global level, regional level and company level. From a global perspective, this report represents overall Irritable Bowel Syndrome (IBS) market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Allergan
    Valeant Pharmaceuticals
    Takeda
    Sucampo Pharmaceuticals
    McNeil Consumer Healthcare
    Sebela Pharmaceuticals
    Astellas Pharmaceuticals
    IM HealthScience

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    IBS-D Drug
    IBS-C Drug
    Other

Segment by Application
    Women
    Men